5241-58-7

Basic information

• Product Name: H-PHE-NH2
• Synonyms: H-PHE-NH2;H-L-PHE-NH2;L-PHENYLALANINE AMIDE;L-PHENYLALANINAMIDE;PHENYLALANINE-NH2;L-phenylalaninamide free base;H-Phe-Nh;2-Amino-3-phenylpropanamide
• CAS NO: 5241-58-7
• Molecular Formula: C₉H₁₂N₂O
• Molecular Weight: 164.2
• Product Categories: Phenylalanine [Phe, F];Amino Acids and Derivatives;Amino Acid Derivatives;Peptide Synthesis;Phenylalanine;Amino Acids;I - Z;Modified Amino Acids;Amino Acids & Derivatives;Aromatics;Chiral Reagents
• Mol File: 5241-58-7.mol
• Article Data: 60

Chemical Properties

• Melting Point: 93-95°C
• Boiling Point: 356.9 °C at 760 mmHg
• Flash Point: 169.7 °C
• Appearance: White/Powder
• Density: 1.143 g/cm³
• Storage Temp.: −20°C
• PKA: 15.85±0.50(Predicted)
• BRN: 6270941
• CAS DataBase Reference: H-PHE-NH2(CAS DataBase Reference)
• NIST Chemistry Reference: H-PHE-NH2(5241-58-7)
• EPA Substance Registry System: H-PHE-NH2(5241-58-7)

Safety Data

• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 5241-58-7(Hazardous Substances Data)

Usage

Chemical Properties

Off-White Solid

Definition

ChEBI: An amino acid amide derived from L-phenylalanine.

InChI:InChI=1/C9H12N2O/c10-8(9(11)12)6-7-4-2-1-3-5-7/h1-5,8H,6,10H2,(H2,11,12)/t8-/m0/s1

Upstream product

• 63-91-2 L-phenylalanine 
• 543-27-1 isobutyl chloroformate 
• 65864-22-4 (S)-2-amino-3-phenylpropionamide hydrochloride 
• 513-49-5 (S)-2-aminobutane 
• 13250-12-9 (R)-sec-butylamine 
• 673-06-3 D-(R)-phenylalanine 
• 18942-49-9 Boc-D-Phe-OH 
• 129095-62-1 (R)-tert-butyl (1-amino-1-oxo-3-phenylpropan-2-yl)carbamate 
• 2577-90-4 methyl (2S)-2-amino-3-phenylpropanoate 
• 84621-26-1 N-(hydroxy(methyl)phosphinyl)-L-phenylalanine amide, sodium salt 
• 17193-31-6 (R,S)-2-amino-3-phenylpropionamide 
• 71666-94-9 (R)-2-amino-3-phenylpropanamide hydrochloride 
• 2448-45-5 Cbz-D-Phe 
• 155385-80-1 (-)-1-(2-phenyl-ethylideneamino)-2R-methyl-5R-(1-methylethenyl)cyclohexane-1R,3R-dicarbonitrile 

Downstream Products

• 120636-88-6 [1-(1-carbamoyl-2-phenylethylcarbamoyl)-2-methylbutyl]carbamic acid tert-butyl ester 
• 33900-15-1 (2S)-N-[(1S)-2-amino-1-benzyl-2-oxoethyl]-2-[(tert-butoxycarbonyl)amino]-4-methylpentanamide 
• 87128-28-7 methyl ester of malonyl-D-phenylalanine amide 
• 91102-96-4 N-(trifluoroacetyl)-L-phenylalanine amide 
• 116097-77-9 Z-Asp(OMe)-Phe-NH₂ 
• 60058-69-7 (tert-butyloxycarbonyl)-β-benzyl-L-aspartyl-L-phenylalanine amide 
• 127479-03-2 ethyloxalamido-2 phenyl-3 propionamide 
• 291311-51-8 Ac-Ala-Ser[β-Gal(OAc)4]-Phe-NH2 

Relevant articles and documents

Mechanism of fluorescence quenching of tyrosine derivatives by amide group

The difference between fluorescence lifetimes of the following amino acids: phenylalanine (Phe), tyrosine (Tyr), (O-methyl)tyrosine (Tyr(Me)), (3-hydroxy)tyrosine (Dopa), (3,4-dimethoxy)phenylalanine (Dopa(Me)2) and their amides was used to tes

Guanidine-containing compound as well as preparation method and application thereof

The invention discloses a cyanoguanidine-containing compound as well as a preparation method and application thereof. The invention also discloses a composition containing the cyanoguanidine-structured compound (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. The invention also discloses application thereof in preparation of analgesic drugs. The compounds of the invention are useful in the treatment of various pain.

Mapping the s1 and s1’ subsites of cysteine proteases with new dipeptidyl nitrile inhibitors as trypanocidal agents

The cysteine protease cruzipain is considered to be a validated target for therapeutic intervention in the treatment of Chagas disease. A series of 26 new compounds were designed, synthesized, and tested against the recombinant cruzain (Cz) to map its S1/S1′ subsites. The same series was evaluated on a panel of four human cysteine proteases (CatB, CatK, CatL, CatS) and Leishmania mexicana CPB, which is a potential target for the treatment of cutaneous leishmaniasis. The synthesized compounds are dipeptidyl nitriles designed based on the most promising combinations of different moieties in P1 (ten), P2 (six), and P3 (four different building blocks). Eight compounds exhibited a Ki smaller than 20.0 nM for Cz, whereas three compounds met these criteria for LmCPB. Three inhibitors had an EC50 value of ca. 4.0 μM, thus being equipotent to benznidazole according to the antitrypanosomal effects. Our mapping approach and the respective structure-activity relationships provide insights into the specific ligand-target interactions for therapeutically relevant cysteine proteases.